Sonia Gill, MD
Clinical Neurophysiology · Fairfax, VANPI 1295120293
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by UCB, Inc. at 34.6% of the total.
Across 244 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$3K
- AbbVie$1K
- SK Life Science, Inc.$850
- Medtronic$429
- Neurelis, Inc.$307
- Catalyst Pharmaceuticals, Inc.$282
- plus $2K from 29 others
What the payments were for
- Food & beverage$8,062100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 48 | $2,798 |
| AbbVie | 72 | $1,173 |
| SK Life Science, Inc. | 21 | $850 |
| Medtronic | 4 | $429 |
| Neurelis, Inc. | 5 | $307 |
| Catalyst Pharmaceuticals, Inc. | 10 | $282 |
| Lilly USA, LLC | 10 | $215 |
| Eisai Inc. | 9 | $187 |
| Merz Pharmaceuticals, LLC | 8 | $186 |
| Jazz Pharmaceuticals Inc. | 2 | $186 |
| Sumitomo Pharma America, Inc. | 5 | $123 |
| Kyowa Kirin, Inc. | 5 | $119 |
| Amgen | 1 | $119 |
| Neuropace, Inc. | 1 | $108 |
| Harmony Biosciences LLC | 4 | $104 |
| Acadia Pharmaceuticals Inc | 4 | $92 |
| Aucta Pharmaceuticals, Inc. | 1 | $80 |
| Livanova USA, Inc. | 2 | $78 |
| Acorda Therapeutics, Inc | 4 | $75 |
| Amneal Pharmaceuticals LLC | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $52 |
| Adamas Pharmaceuticals, Inc. | 2 | $44 |
| Avion Pharmaceuticals | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Corium, LLC | 2 | $40 |
| Insightec,inc | 2 | $33 |
| GE HealthCare | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Pfizer | 1 | $29 |
| Biogen | 1 | $27 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Briviact$391
- Nayzilam$364
- PERCEPT PC BRAINSENSE$344
- VALTOCO$251
- XCOPRI$249
- Fintepla$207
- AIMOVIG$119
- Fycompa$111
- Epidiolex$108
- RNS Neurostimulator Kit$108
How this compares
Too few clinical neurophysiology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 114 | $180,857 |
| Nurtec OdtRimegepant Sulfate | 24 | $43,505 |
| UbrelvyUbrogepant | 23 | $39,090 |
| BriviactBrivaracetam | 15 | $35,817 |
| ValtocoDiazepam | 13 | $35,270 |
| FycompaPerampanel | 22 | $31,840 |
| Lacosamide | 103 | $24,921 |
| NayzilamMidazolam | 14 | $17,085 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,842 |
| Levetiracetam | 169 | $6,731 |
| Oxcarbazepine | 22 | $1,357 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $936 |
| Levetiracetam ErLevetiracetam | 23 | $874 |
| RizatriptanRizatriptan Benzoate | 44 | $866 |
| Pregabalin | 16 | $540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $850 | $180,857114 claims |
| UCB, Inc.Briviact, Nayzilam | $2,798 | $52,90229 claims |
| PfizerNurtec Odt | $29 | $43,50524 claims |
| AbbVieUbrelvy | $1,173 | $39,09023 claims |
| Neurelis, Inc.Valtoco | $307 | $35,27013 claims |
| Eisai Inc.Fycompa | $187 | $31,84022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Fairfax
- Paul LyonsWinchester$171K
- Henry Martin-YeboahAlexandria$3K
- Eric GoldbergPortsmouth$2K
- Divya ChauhanLeesburg$525
- Noor MozahemRichmond$136
- Saba NawazRichmond$136
- Vivek SatyasiManassas$87
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.